Globus Medical price target raised to $85 from $83 at Barclays

Barclays raised the firm’s price target on Globus Medical to $85 from $83 and keeps an Overweight rating on the shares. The company delivered 9% organic sales growth against a challenging 21% prior year comp, the analyst tells investors in a research note. The firm expects the stock to re-rate higher from its current valuation.